Emerging safety issues in alemtuzumab-treated MS patients.
作者信息
Killestein Joep, van Oosten Bob
机构信息
Department of Neurology, Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
出版信息
Mult Scler. 2019 Aug;25(9):1206-1208. doi: 10.1177/1352458519851219.
Abstract
摘要
相似文献
1
Emerging safety issues in alemtuzumab-treated MS patients.阿仑单抗治疗的多发性硬化症患者中出现的安全性问题。
Mult Scler. 2019 Aug;25(9):1206-1208. doi: 10.1177/1352458519851219.
2
[The use of music therapy in the treatment of adverse effects in patients with multiple sclerosis treated with alemtuzumab].[音乐疗法在治疗接受阿仑单抗治疗的多发性硬化症患者不良反应中的应用]
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(7. Vyp. 2):73-76. doi: 10.17116/jnevro202012007273.
3
Alemtuzumab: Rare serious adverse events of a high-efficacy drug.阿仑单抗：一种高效药物的罕见严重不良事件。
Mult Scler. 2020 May;26(6):737-740. doi: 10.1177/1352458520913277. Epub 2020 Apr 16.
4
Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017.回应：S. 塞加 - 亚兹贝克等人：“多发性硬化症患者中与阿仑单抗相关的输液相关反应的管理” 《多发性硬化症及相关疾病》2017年。
Mult Scler Relat Disord. 2017 Oct;17:177-178. doi: 10.1016/j.msard.2017.08.001. Epub 2017 Aug 9.
5
Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.用于治疗多发性硬化症的阿仑单抗输注时即刻出现的血小板减少症——并非总是自限性、完全可逆或可预测的。
Mult Scler. 2018 Apr;24(4):552-553. doi: 10.1177/1352458517719151. Epub 2017 Jun 29.
6
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).评估在接受阿仑单抗（EMERALD）治疗的复发性缓解型多发性硬化症（RRMS）患者中预防和管理输注相关反应（IARs）的综合输注指导的单臂研究。
Mult Scler Relat Disord. 2019 Apr;29:7-14. doi: 10.1016/j.msard.2019.01.019. Epub 2019 Jan 6.
7
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
8
Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab.阿仑单抗治疗后改用奥瑞珠单抗的格雷夫斯病缓解。
Acta Neurol Belg. 2022 Aug;122(4):1117-1120. doi: 10.1007/s13760-022-01962-9. Epub 2022 May 19.
9
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).在德国开展的一项关于阿仑单抗治疗多发性硬化症患者的安全性、有效性、生活质量、认知、健康相关及工作能力数据的非干预性研究的基本原理、设计与方法（TREAT-MS研究）
BMC Neurol. 2016 Jul 19;16:109. doi: 10.1186/s12883-016-0629-9.
10
Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.作者回复：阿仑单抗CARE-MS II 5年随访：疗效与安全性结果。
Neurology. 2018 Sep 18;91(12):581-582. doi: 10.1212/WNL.0000000000006203.
引用本文的文献
1
Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.奥天时的阿仑单抗医治多发性软化症：一项观测性长时刻结局研讨。
Ann Clin Transl Neurol. 2024 Jun;11(6):1442-1455. doi: 10.1002/acn3.52056. Epub 2024 May 7.
2
Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study.与多发性硬化症的疾病修正药物相关的不良事件：一项多区域基于人群的研究。
Neurology. 2024 Feb 13;102(3):e208006. doi: 10.1212/WNL.0000000000208006. Epub 2024 Jan 5.
3
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.用于复发型多发性硬化症治疗的克拉屈滨片安全性专家叙述性综述
Neurol Ther. 2023 Oct;12(5):1457-1476. doi: 10.1007/s40120-023-00496-3. Epub 2023 Jun 29.
4
The Heart-Brain Interplay in Multiple Sclerosis from Pathophysiology to Clinical Practice: A Narrative Review.从病理生理学到临床实践的多发性硬化症中的心脑相互作用：一篇叙述性综述
J Cardiovasc Dev Dis. 2023 Apr 1;10(4):153. doi: 10.3390/jcdd10040153.
5
Multiple Sclerosis and Autoimmune Comorbidities.多发性硬化症与自身免疫性共病
J Pers Med. 2022 Nov 3;12(11):1828. doi: 10.3390/jpm12111828.
6
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.免疫重建疗法在法国复发型多发性硬化症管理中的地位：专家共识
Neurol Ther. 2023 Apr;12(2):351-369. doi: 10.1007/s40120-022-00430-z. Epub 2022 Dec 24.
7
NDRG1 is induced by antigen-receptor signaling but dispensable for B and T cell self-tolerance.NDRG1 可被抗原受体信号诱导，但对 B 和 T 细胞自身耐受并非必需。
Commun Biol. 2022 Nov 10;5(1):1216. doi: 10.1038/s42003-022-04118-w.
8
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.单克隆抗体在复发性多发性硬化症治疗中的应用：重点关注妊娠、疫苗接种和风险管理的概述。
Neurotherapeutics. 2022 Apr;19(3):753-773. doi: 10.1007/s13311-022-01224-9. Epub 2022 Apr 4.
9
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.自身免疫性神经肌肉接头疾病中的抗体治疗：肌无力危象和慢性管理的方法。
Neurotherapeutics. 2022 Apr;19(3):897-910. doi: 10.1007/s13311-022-01181-3. Epub 2022 Feb 14.
10
Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.诱发或导致重症肌无力病情恶化的药物：最新进展
J Clin Med. 2021 Apr 6;10(7):1537. doi: 10.3390/jcm10071537.
本文引用的文献
1
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.在多发性硬化症患者中使用阿仑单抗治疗后的自身免疫性肾病的发病率、处理方法和结局。
Mult Scler. 2019 Aug;25(9):1273-1288. doi: 10.1177/1352458519841829. Epub 2019 Apr 15.
2
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.多发性硬化症的当前治疗格局：不断发展的治疗范例。
Curr Opin Neurol. 2019 Jun;32(3):365-377. doi: 10.1097/WCO.0000000000000700.
3
Intracerebral haemorrhage during alemtuzumab administration.使用阿仑单抗期间发生的脑出血。
Lancet Neurol. 2019 Apr;18(4):329-331. doi: 10.1016/S1474-4422(19)30076-6. Epub 2019 Feb 15.
4
Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.在接受阿仑单抗输注 23 天后，一位多发性硬化症患者出现中性粒细胞减少伴致命结局。
Mult Scler Relat Disord. 2018 Jul;23:15-16. doi: 10.1016/j.msard.2018.04.014. Epub 2018 Apr 28.
5
Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.2例接受阿仑单抗治疗的多发性硬化患者发生噬血细胞性淋巴组织细胞增生症。
Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30.
6
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.监测和管理接受阿仑单抗治疗的多发性硬化症患者的自身免疫：实用建议。
J Neurol. 2018 Nov;265(11):2494-2505. doi: 10.1007/s00415-018-8822-y. Epub 2018 Mar 10.
7
Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.用阿仑单抗治疗的多发性硬化症患者的中性粒细胞减少症
JAMA Neurol. 2017 Sep 1;74(9):1143-1144. doi: 10.1001/jamaneurol.2017.1456.
8
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.解读阿仑单抗关键3期试验中的淋巴细胞重建数据。
JAMA Neurol. 2017 Aug 1;74(8):961-969. doi: 10.1001/jamaneurol.2017.0676.
9
Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.阿仑单抗治疗继发的严重B细胞介导的中枢神经系统疾病。
Lancet Neurol. 2017 Feb;16(2):104-106. doi: 10.1016/S1474-4422(16)30382-9.
10
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
Zotero 插件